Delivery Order SPE2DB22D9207-SPE2DB25FH4VE

Award Date 1/7/25
Potential Completion Date 1/8/25
Potential Value $26K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) under the Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of XTANDI 40 MG CAPSULE 120S, with a ceiling value of $4,311.35 and a period of performance through July 3, 2024. The award is a firm fixed-price delivery order. DMS Pharmaceutical Group holds a larger indefinite delivery contract...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a branded pharmaceutical product. The award has a ceiling value of $25,868.10 and a completion date of September 5, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 order is for the delivery of XTANDI 40 MG CAPSULE 120S, with a completion date of May 20, 2024. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which runs through December 31, 2025. This...
This is a firm fixed price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,868.10 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a prescription medication, and is not associated with any set-aside program. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, that allows...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $43,113.50 firm fixed-price contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a branded pharmaceutical product. The order has a completion date of June 14, 2024. DMS Pharmaceutical Group holds a larger, single-award indefinite delivery contract (IDC) with the DLA, valued at up to...
The U.S. Defense Logistics Agency (DLA) has awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $12,934.05, is for the delivery of XTANDI 40 MG CAPSULE 120S. This order is placed under a larger indefinite delivery contract (IDC) with DMS Pharmaceutical Group held by the DLA, valued at up to $499,999,999 and running through December 31, 2025. The IDC...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $4,311.35, is for the supply of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product. The delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and the DLA, valued at up to $499,999,999, which allows the DLA to issue...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $33,923.76, is for the delivery of XTANDI 40 MG CAPSULE 120S over the period of September 10, 2024 to September 10, 2024. DMS Pharmaceutical Group Inc. holds a larger single-award indefinite delivery contract (IDC) with the DLA under the SPE2DB program,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $4,311.35 firm fixed-price contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product, with a completion date of May 15, 2024. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at up to $499,999,999,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a for-profit, woman-owned small business based in Park Ridge, Illinois. The $34,490.80 contract is for the delivery of XTANDI 40 MG CAPSULE 120S, a pharmaceutical product. The contract has a completion date of February 29, 2024. DMS Pharmaceutical Group holds an indefinite delivery contract (IDC) with the DLA, contract 4600082013 under the SPE2DB program, valued at up to...
  • SPE2DB22D9207
    Indefinite Delivery Contract
  • SPE2DB22D9207-SPE2DB25FH4VE
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the supply of XTANDI 40 MG CAPSULE 120S, a specialty pharmaceutical product, with a ceiling value of $25,868.10. The contract is a firm fixed-price delivery order with a period of performance through January 8, 2025. DMS Pharmaceutical Group Inc. holds a significant single-award Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military health facilities worldwide. This contract is not associated with any set-aside designation.

Generated 4/8/25, 9:42 AM